TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

The Motley Fool Logo The Motley Fool By Prosper Junior Bakiny
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

Intellia Therapeutics, a biotech company developing gene-editing therapies for rare diseases, faces significant risks after pausing clinical trials due to a patient experiencing liver damage. Despite potential blockbuster drug candidates, the stock's future remains uncertain.

Insights
PYPL   neutral

Mentioned in report without specific regional performance details


NTLA   negative

The company experienced a major clinical trial setback with nex-z, which was paused due to a patient suffering liver damage. While the drugs have potential billion-dollar market opportunities, the safety concerns and high risk of failure in clinical-stage biotech make the outlook uncertain.